David McCue

Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline ‘chemotherapy-free’ therapy

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Leukemia & lymphoma.

Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study

M. Konopleva, Z. Estrov, Xuelin Huang, 2021 .

Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study.

M. Konopleva, H. Kantarjian, Xuelin Huang, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia.

K. Coombes, Z. Estrov, S. Kornblau, 2010, Blood.

Activation thresholds determine susceptibility to peptide-induced tolerance in a heterogeneous myelin-reactive T cell repertoire

D. Wraith, S. Anderton, K. Ryan, 2004, Journal of Neuroimmunology.

Fas‐mediated death and sensory adaptation limit the pathogenic potential of autoreactive T cells after strong antigenic stimulation

S. Anderton, K. Ryan, David McCue, 2005, Journal of leukocyte biology.

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

E. Estey, M. Konopleva, Z. Estrov, 2017, Blood.

Validation of Salivary Interleukin-6 and Tumor Necrosis Factor-Alpha of Healthy Adult Volunteers by Enzyme Immunoassay

S. Hanneman, David McCue, Gabriel L. Blog, 2016, Nursing research.

Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.

H. Kantarjian, K. Patel, F. Ravandi, 2024, Leukemia & lymphoma.